{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 83 of 92', 'CR845-CLIN3103', '13.0', 'References', 'Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical', 'trials. Biometrics. 1999;55(3):853-7.', 'Criteria Committee of the New York Heart Association. Nomenclature and Criteria for', 'Diagnosis of Diseases of the Heart and Great Vessels. Edition Number 9. Little, Brown &', 'Co; Boston, Mass: 1994. pp. 253-6.', 'Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical', 'trials: IMMPACT recommendations. Pain. 2005;113(1-2):9-19', 'Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus.', 'Br J Dermatol. 2010;162(3):587-93', 'Guidance for Industry. Determining the extent of safety data collection needed in late-', 'stage premarket and postapproval clinical investigations. US Department of Health and', 'Human Services, Food and Drug Administration, Center for Drug Evaluation and', 'Research (CDER), Center for Biologics Evaluation and Research (CBER). February', '2016.', \"Investigator's Brochure. CR845 (Difelikefalin). Edition Number 8. 7 November 2017.\", 'Kimmel M, Alscher DM, Dunst R, et al. The role of micro-inflammation in the', 'pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant.', '2006;21(3):749-55.', 'Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a', 'novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in', '337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled', 'study. NDT. 2010;25(4):1251-7.', 'Mathur VS, Lindberg J, Germain M, et al. A longitudinal study of uremic pruritus in', 'hemodialysis patients. Clin J Am Soc Nephrol. 2010;5(8): 1410-9.', 'Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus-new perspectives and', 'insights from recent trials. Nephrol Dial Transplant. 2002; 17(9): 1558-63.', 'Narita I, Alchi B, Omori K, et al. Etiology and prognostic significance of severe uremic', 'pruritus in chronic hemodialysis patients. Kidney Int. 2006;69(9):1626-32.', 'Patel TS, Freedman BI, Yosipovitch G. An update on pruritus associated with CKD.', 'Am J Kidney Dis. 2007;50(1):11-20', 'Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on', 'validity and reliability of the visual analogue scale, numerical rating scale and verbal', 'rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502-7.', 'Pisoni RL, Wikstrom B, Elder SJ, et al. Pruritus in haemodialysis patients: International', 'results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial', 'Transplant. 2006;21(12):3495-505.', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 84 of 92', 'CR845-CLIN3103', 'St\u00e4nder S, Augustin M, Reich A, et al. Pruritus Assessment in clinical trials: consensus', 'recommendations from the International Forum for the Study of Itch (IFSI) Special', 'Interest Group Scoring Itch in Clinical Trials. Acta Derm Venereol. 2013;93(5):509-14.', 'Tey HL, Yosipovitch G. Targeted treatment of pruritus: a look into the future. Br J', 'Dermatol. 2011;165(1):5-17.', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}